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Abstract: Neuroimaging studies of cholinesterase inhibitor (ChEI) treatment in Alzheimer’s 
disease (AD) indicate that the short and long term actions of ChEIs are dissimilar. fMRI studies 
of the ChEI rivastigmine have focused on its short term action. In this exploratory study the 
effect of prolonged (20 weeks) rivastigmine treatment on regional brain activity was measured 
with fMRI in patients with mild AD. Eleven patients with probable AD and nine age-matched 
controls were assessed with a Pyramids and Palm Trees semantic association and an n-back 
working memory fMRI paradigm. In the patient group only, the assessment was repeated after 
20 weeks of treatment. There was an increase in task-related brain activity after treatment with 
activations more like those of normal healthy elderly. Behaviorally, however, there were no 
signiﬁ cant differences between baseline and retest scores, with a range of performance prob-
ably reﬂ ecting variation in drug efﬁ cacy across patients. Variable patient response and drug 
dynamic/kinetic factors in small patient groups will inevitably bias (either way) the effect size 
of any relevant drug related changes in activation. Future studies should take drug response into 
account to provide more insight into the beneﬁ ts of ChEI drugs at the individual level.
Keywords: fMRI, rivastigmine, treatment, dementia, Alzheimer’s disease
Introduction
Brain imaging has gained some credibility in the last decade, at least in research 
settings, in the evaluation of the effects of cholinesterase inhibitor (ChEI) treatment 
in Alzheimer’s disease (AD) (see Venneri 2007 for a recent review). The modest 
beneﬁ cial effects of ChEIs on certain cognitive and behavioural symptoms typical of 
AD have been established in several clinical trials (Birks et al 2000a, 2000b; Wilcock 
et al 2000). These studies generally overlooked the marked variation in the degree of 
clinical response and failed to clarify the reasons for more substantial clinical beneﬁ t 
in some patients. Positron emission tomography (PET) and single photon emission 
computed tomography (SPECT) studies have established that increases in brain blood 
ﬂ ow, metabolism, and preservation of receptor function in regions of the cerebral 
cortex seem to follow a favorable response to treatment (Potkin et al 2001; Nobili 
et al 2002a, 2002b; Venneri et al 2002; Lojkowska et al 2003; Stefanova et al 2006; 
Kadir et al 2007). In some instances, a correlation between clinical improvements and 
regional increases in brain blood ﬂ ow or metabolism in task meaningful areas has been 
found (Venneri and Shanks 2002; Kadir et al 2006). In most cases, however, any link 
between cognitive improvements and changes in parameters of cerebral function has 
been only indirectly established.
In an attempt to overcome this limitation a few small studies have used functional 
magnetic resonance imaging (fMRI) with cognitive activation paradigms to poten-
tially establish a direct link between cholinergic enrichment and improved task related 
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brain activation. For example, two small groups of patients 
with AD were scanned with fMRI before and after a single 
cholinergic challenge with a dose of rivastigmine. One group 
was tested with a face encoding paradigm, while the other 
was tested with a working memory paradigm (Rombouts et al 
2002). Both groups showed increased regional activation in 
task relevant areas after receiving the drug. These observa-
tions were taken as evidence that the increased performance 
on the cognitive tests recorded in clinical studies was most 
likely an indication of a speciﬁ c effect of rivastigmine on 
neuronal activity. Similar ﬁ ndings have been reported in 
an fMRI study with patients with mild cognitive impair-
ment (MCI) and in patients with AD following a few weeks 
of treatment with the ChEI donepezil (Saykin et al 2004; 
Kircher et al 2005).
Most of this research, however, involved assessment after 
either an acute challenge or only a few weeks of treatment 
with a ChEI. Short treatment periods are inconsistent with 
clinical studies and might not sufﬁ ciently clarify the mecha-
nisms underlying clinical change. For example, when the 
effects of acute, repeated and prolonged treatment have been 
examined with fMRI, the results appear to indicate that the 
short term and long term actions of this class of drugs are dis-
similar. Evidence of this kind is available for galantamine but 
not for the other two ChEIs. Single dose challenge and ﬁ ve 
day treatment with galantamine in MCI and AD have given 
disparate results which may not only reﬂ ect experimental 
variables, but may also disclose important pharmacokinetic 
information. In one study of MCI, increases in brain activa-
tion were found after the ﬁ ve day treatment, but not after 
an acute challenge with galantamine (Goekoop et al 2004). 
A subsequent study on MCI and AD, by the same authors, 
showed that signiﬁ cant increases in brain activation were 
only present after an acute single dose challenge, but not after 
more prolonged exposure to galantamine, which in this case 
caused decreases in brain activation (Goekoop et al 2006). In 
contrast, increased brain activation was reported in patients 
with MCI when they were reassessed with a navigation 
fMRI paradigm after seven day treatment with galantamine 
(Gron et al 2006). Only one study has reported effects on 
brain activation following treatment with galantamine for a 
period comparable with the brain blood ﬂ ow and metabolism 
studies. There was a modest restoration of regional task rel-
evant brain activation for both the fMRI paradigms (testing 
semantic and attention skills) used, which was paralleled by 
a minor, statistically not signiﬁ cant, improvement in behav-
ioral scores (Shanks et al 2007). This research evidence ﬂ ags 
up the importance of taking into account a pharmacokinetic 
trajectory, which may be uniquely characteristic of a given 
ChEI, in order to establish the time course of measurable 
effects on the chosen brain parameters and to better ensure 
that imaging variables represent a valid surrogate outcome 
measure of drug efﬁ cacy in AD.
The aim of this small exploratory study, therefore, 
was to investigate the action of prolonged (over 20 weeks) 
treatment with rivastigmine on the blood oxygenation level 
dependent (BOLD) signal measured by fMRI in patients 
with mild AD.
Methods
Participants
The participants were eleven patients with probable AD and 
nine elderly age-matched controls. The patients with AD 
were selected from approximately one hundred patients with 
memory problems referred to an old age psychiatry memory 
clinic. The patients had psychiatric assessment, neurological 
examination, extensive neuropsychological screening and 
structural MRI scanning. All patients entering the fMRI study 
fulﬁ lled the NINCDS-ADRDA criteria for probable AD 
(McKhann et al 1984) of minimal to mild severity and none 
had radiological evidence of ischemic brain disease. Those 
patients in the minimal stage did not meet the criteria for 
mild cognitive impairment (MCI) (Petersen et al 1997) as all 
showed typical progressive cognitive decline during clinical 
follow ups and had signiﬁ cant deﬁ cits in activities of daily 
living. Exclusion criteria included claustrophobia, Hachinski 
Ischemia scale score greater than four (Hachinski et al 1975), 
Mini Mental State Examination (MMSE) scores of less than 
18/30 (Folstein et al 1975), other types of degenerative or 
secondary dementia as assessed with current clinical diag-
nostic criteria (Roman et al 1993; Brun et al 1994; McKeith 
et al 1996). The AD group consisted of seven males and four 
females between the ages of 69 and 95, with a mean age of 
79.00 (SD 7.44). Their education ranged from 9 to 17 years 
(mean 11.55, SD 3.27). The elderly control group included 
three males and six females between the ages of 72 and 77 
with a mean age of 75.11 (SD 1.62) and with education 
between 10 and 17 years (mean 11.67, SD 2.29). Elderly 
controls were recruited from a panel of healthy participants 
with no history of neurological or psychiatric illness, who 
had been volunteering to take part in research for a number 
of years and for whom extensive longitudinal cognitive 
assessment was available. All individuals in this group scored 
27/30 or greater on the MMSE. The participants were all right 
handed. Consent was obtained from each participant prior 
to the experiment and ethical approval was granted by the 
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regional Ethics Committee. Two patients withdrew consent 
to reassessment with fMRI. The patients were both female 
aged 69 and 76, with similar educational background and 
their MMSE scores were 21 and 26.
Assessments
Clinical and neuropsychological
Each of the patients completed a comprehensive neuropsy-
chological test battery, as well as MMSE, the Alzheimer’s 
Disease Assessment Scale cognitive subscale (ADAS-Cog), 
the Neuropsychiatric Inventory (NPI) with caregiver distress 
scale, the Geriatric Depression Scale (GDS), Activities of 
Daily Living (ADL) scale completed by patient and caregiver 
independently, as well as the Clinician’s Interview-Based 
Impression of Change – Plus (CIBIC-Plus) at baseline and 
at retest after twenty weeks treatment. Following baseline 
diagnostic and research assessment the patients began treat-
ment with rivastigmine, and the dosage titrated according to 
recommended guidelines. Stable dosing was achieved at 6 mg 
twice daily for all patients.
fMRI
All patients and the elderly controls were assessed with two 
cognitive activation fMRI paradigms (see below) at baseline, 
and the assessment was repeated after 20 weeks treatment in 
the patient group. During the selection process the elderly 
controls and patients with AD were acquainted with the 
MRI environment and the task requirements in a full size 
MRI simulator. Patients and healthy participants were also 
presented with examples of the stimuli (both activation and 
baseline conditions) on sheets of card and reminded of the 
instructions immediately before active scanning. Once the 
patients and controls were relaxed in the scanner and familiar 
with the procedure, the experiment began.
fMRI acquisition and analysis
Echo planar imaging was carried out on a GE 1.5T Signa 
Cvi system (TR = 2500 ms, TE = 35 ms, ﬂ ip angle α = 
90°, voxel size = 1.88 × 1.88 mm in plane resolution). One 
hundred and twenty sets of 23 contiguous 5 mm thick axial 
images were acquired twice for both the semantic association 
task and the working memory task. Stimulus presentation 
was driven by a PC with a purpose devised program written 
using Presentation for Windows. Stimuli were projected 
via an Epson LCD projector onto a screen viewable with 
a mirror attached to a standard head coil. The participants 
were equipped with a ﬁ bre optic response device in both 
the left and right hand for recording behavioural responses. 
An experimental paradigm which followed a block design 
was used in both tasks. Total time in the scanner for the two 
activation paradigms, localizer and T1 weighted axial images 
was approximately 30 minutes.
Imaging data were analyzed using Statistical Paramet-
ric Mapping (SPM2) image analysis software (Wellcome 
Department of Imaging Neuroscience, London). All volumes 
from each subject were re-aligned and re-sliced using sinc 
interpolation methods to adjust for residual motion related 
signal changes. Images were spatially normalized to the 
standard EPI template available in SPM2 using nonlinear 
estimation of parameters. Normalized images were then 
spatially smoothed with an 8 mm full width at half maximum 
isotropic Gaussian kernel to compensate for any residual 
variability after spatial normalization. A boxcar waveform 
convolved with a synthetic hemodynamic response function 
(HRF) was used as the reference waveform for each condi-
tion. Proportional scaling was applied to remove any within 
subject difference in blood ﬂ ow. Image data were high-pass 
ﬁ ltered with a set of discrete cosine basis functions with a cut-
off period of 128 s. Head motion parameters were included 
as regressors in the ﬁ rst level analyses. The second level 
group analyses were carried out using the contrast images 
generated at the individual level analysis. Individual group 
analyses were carried out with one sample t-tests, within 
group baseline-after treatment comparisons were completed 
with paired sample t-tests, and between group comparisons 
with independent sample t-tests. For both fMRI paradigms 
there are a number of published studies which can be used 
as a reference for the areas which should be signiﬁ cantly 
activated. Based on a priori hypotheses, threshold was 
adjusted in the elderly group to p  0.02 corrected for the 
semantic association task and p  0.005 corrected for the 
working memory task. For the within and between group 
comparisons a threshold of p  0.05 corrected was chosen for 
both tasks. Unless otherwise speciﬁ ed these thresholds were 
used for all the results reported below. Age was included as 
a covariate in the fMRI analyses. Anatomical regions were 
identiﬁ ed using the Talairach Daemon Client (http://ric.
uthscsa.edu/projects/tdc/), following appropriate conversion 
of the Montreal Neurological Institute coordinates extracted 
from the SPM analysis into Tailarach coordinates.
fMRI paradigms
Semantic association task
The paradigm followed a block design with two alternating 
conditions (activation and baseline). The stimuli for the acti-
vation conditions were selected from the word version of the 
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Pyramids and Palm Trees Test (Howard and Patterson 1992). 
The word version of this test was used because it had lower 
perceptual demands than the picture version. The test stimuli 
were presented on a white background as in the original 
conﬁ guration except for presenting the target word in blue 
and the alternative choices in red to facilitate discrimination 
between the target element and the alternative choices. The 
participant responded by pressing the button corresponding 
to their choice either with the left or right hand.
The baseline task consisted of nonword stimuli with a 
conﬁ guration similar to those of the active condition and the 
participant had to make a simple visual discrimination by 
responding to the stimulus marked with a star. This simple 
perceptual judgment was chosen after extensive pilot testing 
showed that this task was easier to understand for the patients 
and clearly differed from the requirements of the active 
condition. In both activation and baseline conditions the 
number of appropriate left and right responses was balanced. 
Instructions for each condition were presented for ﬁ ve seconds, 
followed by the test stimuli. The presentation screen was 
white and the instructions were displayed in a black Times 
New Roman font type. The stimuli were on screen for 4500 
ms, with an inter-stimulus interval of 500 ms and remained 
on screen even after a response had been made. Nine stimuli 
for each condition were presented in each epoch. This cycle 
of active and baseline conditions was repeated three times in 
each run. The order of the conditions was ﬁ xed. Each condition 
lasted 50 seconds. Total scanning time for each run was ﬁ ve 
minutes. Ten seconds of dummy scans were acquired before 
each run to enable the scanner to reach equilibrium.
Working memory task
In this paradigm a series of letters were presented. There 
were two conditions, the ﬁ rst (the baseline condition) 
included a ﬁ ve second presentation of instruction followed 
by 18 letters presented serially (in the centre of the screen) 
for 2000 ms each, with a blank screen inter-stimulus inter-
val of 500 ms. The participant had to attend to the letters 
and press the response button only when the letter X was 
presented. The light working memory load (activation) 
condition began with a ﬁ ve second instruction screen fol-
lowed by 18 single letter stimuli. Each was presented for 
2000 ms with a blank screen inter-stimulus interval of 500 
ms. In this activation condition participants were instructed 
to respond every time a letter was repeated in the sequence 
(1-back task). Only consonants were used. This cycle of 
baseline and activation conditions was repeated three times 
in each run. The order of the two conditions was ﬁ xed. Each 
condition lasted 50 seconds. Total scanning time for each 
run was ﬁ ve minutes. Ten seconds of dummy scans were 
acquired before each run to enable the scanner to reach 
equilibrium.
Results
Independent samples t-tests revealed no signiﬁ cant differ-
ences in age and education between the elderly control group 
and the patient group (t
(8.782)
 = 2.140; ns and t
(16)
 = .241; ns 
respectively). As expected the MMSE scores of the elderly 
group (mean 28.89, SD 0.93) were signiﬁ cantly higher 
(t 
(9.368)
 = −4.754, p  0.001).
The elderly group performed at a high level on the seman-
tic association task (mean percentage correct 84.57, SD 6.74, 
mean response time 1906.17 ms, SD 213.65 ms) and the 
working memory task (mean percentage correct 98.86, SD 
3.21, mean response time 486.97 ms, SD 80.34 ms).
Clinical and behavioral assessment in the 
AD group
Paired sample t-test analyses showed that the only signiﬁ cant 
difference between the mean scores obtained by the patients at 
baseline and retest after treatment, on the cognitive tests and 
clinical scales was that on the ADAS-cog (t
8
 = 5.308; p  0.001), 
scale on which there was an improvement (Table 1).
On the semantic association fMRI task, the baseline 
mean percentage correct score was 65.64 (SD 21.08) with 
a range from 33.33 correct to 85.19, and after treatment the 
mean percentage correct score was 61.94 (SD 24.43) with 
a range from 22.22 to 87.04. Although there was a slight 
decrease in the mean behavioral score at retest after treat-
ment, no signiﬁ cant differences from baseline emerged from 
the analysis (t
8
 = .541, ns). There was a variable response to 
treatment in the group, however, with individual variations 
from baseline score ranging from a −37.03 % reduction to a 
35.19 % increase at retest.
On the working memory task the group mean score 
increased from baseline (mean score 90.34, SD 25.53, range 
27.27 to 100) to retest (mean score 95.45, SD 6.43, range 81.82 
to 100), but the difference was not signiﬁ cant (t
7
 = −0.72, ns) 
(see Table 1). A variable response to treatment was again 
observed. Individual variations from baseline scores ranged 
from a −4.45 % reduction to a 54.55 % increase at retest.
After treatment, there was an increase in mean response 
times compared to the baseline times for the semantic 
association task, but the difference was not significant 
(t
8
 = −1.331, ns). A decrease in response time was present 
for the working memory task; the difference, however, was 
also not signiﬁ cant (t
7
 = 1.038, ns) (see Table 1).
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Semantic association task – fMRI results
Elderly group
Signiﬁ cant activation was found in the left prefrontal cortex, 
the left superior parietal lobule, and the precuneus. Signiﬁ cant 
decreases in activation were found in right temporal regions, 
inferior parietal areas bilaterally, right middle frontal areas, 
the anterior cingulate gyrus bilaterally and the left insula 
(Table 2a and Figure 1a).
AD group
Before treatment the AD patients had one cluster of signiﬁ -
cant activation, the maxima of which were in the left middle 
frontal gyrus. Signiﬁ cant decreases were present in posterior 
regions including the right cuneus and precuneus (Table 2a 
and Figure 1b). After treatment with rivastigmine signiﬁ cant 
activation was present in broadly the same locations, eg, the 
left prefrontal cortex, but the pattern of activation was now 
more extensive, including the left superior frontal gyrus and 
the right inferior frontal gyrus (Table 2a). Signiﬁ cant activa-
tion was also seen in the orbitofrontal cortex and the anterior 
cingulate gyrus bilaterally, areas which were not activated 
at baseline (Figure 1c). Signiﬁ cant decreases in signal after 
treatment were found in the right supramarginal gyrus and the 
right postcentral gyrus.
A direct comparison between the after treatment and 
baseline images in the AD group, although not surviving 
correction for multiple comparisons, identiﬁ ed a number 
of regions which had signiﬁ cantly increased in activation 
after treatment. The locations of these areas were consistent 
with sites which published fMRI studies have reported as 
signiﬁ cantly activated by healthy controls when performing 
a semantic association paradigm similar to that used in the 
present study. Increased activation was found in the left 
inferior frontal gyrus, the left middle temporal gyrus, the 
right superior frontal gyrus and in the middle frontal, the 
fusiform and the parahippocampal gyri bilaterally (Table 2b, 
Figure 2a). The baseline versus retest comparison showed no 
differences surviving a corrected threshold of signiﬁ cance. 
Differences were present in the right postcentral gyrus and 
the right inferior parietal lobule at an uncorrected thresh-
old level. To check whether these differences were due to 
greater deactivation in the AD group after treatment, the 
deactivation pattern from the random effects analysis was 
used as a mask (ie, signiﬁ cant areas of deactivation were 
used as a mask in the analyses to ensure that any signiﬁ cant 
differences referred only to actual increases in activation). 
After masking for deactivation, these differences were no 
longer detectable.
Table 1 Mean (and standard deviation) scores obtained by the AD patients on the cognitive tests, clinical scales and during the fMRI 
tasks, before and after 20 weeks of treatment with rivastigmine
Cognitive tests Baseline Retest
Mini Mental State Examination 23.67 (3.16) 24.89 (3.30)
ADAS-Cog* 19.44 (4.25) 15.22 (5.50)
Raven progressive matrices 24.44 (3.84) 25.29 (3.20)
Paired associate learning 9.22 (2.39) 9.71 (2.14)
Confrontation naming 18.22 (1.72) 18.86 (1.07)
Stroop test 
Error interference score  1.63 (2.00) 1.33 (2.16)
Time interference score (s) 36.06 (11.79) 40.50 (24.07)
Clinical scales
Neuropsychiatric Inventory 15.89 (15.62) 11.11 (10.60)
Geriatric Depression Scale 2.00 (1.85) 2.29 (1.89)
Activities of Daily Living 
Patient assessment  25.38 (3.81) 24.00 (2.88)
Carer assessment 23.14 (5.49) 22.63 (5.18)
CIBIC-Plus  3.11 (0.93)
fMRI behavioral tasks
Semantic association task
Percentage correct 65.64 (21.08) 61.94 (24.43)
Reaction times (ms) 2460.42 (572.54) 2581.52 (423.89)
Working memory task 
Percentage correct  90.34 (25.53) 95.45 (6.43)
Reaction times (ms) 628.74 (299.84)  575.07 (195.34)
Notes: *Signifi cantly different from baseline at p  0.001.
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Table 2 a) Areas of signifi cant differences in brain activation and deactivation in the elderly and in the AD patients (before and after 
20 weeks of treatment with rivastigmine) during the semantic association task. b) Direct within group and between comparisons
a)
Brain area Left/right Brodmann’s Talairach   Z value
  area coordinates  at local
   x y z maximum*
Elderly – activations      
Inferior frontal gyrus L 47 −53 21 −3 3.48
Middle frontal gyrus L 46 −44 21 25 4.93
Superior parietal lobule L 7 −34 −70 46 4.27
Precuneus L 7 −24 −71 53 3.27
Elderly – deactivations      
Inferior parietal lobule L 40 −50 −28 22 4.50
Insula L 13 −44 −4 −1 4.15
Anterior cingulate L 10 −6 38 −7 3.86
Middle frontal gyrus R 11 18 38 −14 4.26
Anterior cingulate R 32 20 39 0 3.85
Postcentral gyrus R 40 63 −24 16 5.33
Middle temporal gyrus R 21 55 −2 −8 4.07
Inferior parietal lobule R 40 65 −30 25 4.30
AD (baseline) – activations      
Middle frontal gyrus L 9, 6, 46 −42 13 27 5.50
AD (baseline) – deactivations      
Precuneus R 31 8 −49 32 4.24
Cuneus R 19 12 −78 30 4.28
AD (after treatment) – activations      
Middle frontal gyrus L 46 −40 19 23 4.04
Superior frontal gyrus L 11 −12 50 −13 4.15
      
Inferior frontal gyrus R 47 30 29 −5 5.06
AD (after treatment) – deactivations      
Postcentral gyrus R 3, 43 65 −12 25 4.26
Supramarginal gyrus R 40 57 −39 30 6.22
b)
Brain area Left/right Brodmann’s Talairach   Z value
  area coordinates  at local
   x y z maximum
AD baseline versus AD after treatment      
(masking for deactivation in AD group after       
treatment)      
No signifi cant differences       
AD after treatment versus AD baseline      
Inferior frontal gyrus L 13, 47 −32 12 −16 2.76
Middle frontal gyrus L 11 −24 40 −2 2.69
Paracentral lobule L 5 0 −34 54 3.15
Postcentral gyrus L 5 −32 −44 60 2.95
Parahippocampal gyrus L 35 −24 −30 −30 3.01
Middle temporal gyrus L 21 −52 −48 −8 3.66
Fusiform gyrus L 20 −30 −38 −28 3.06
(Continued)
Neuropsychiatric Disease and Treatment 2008:4(2) 471
Rivastigmine modulates brain activity in AD
Elderly/AD group comparisons
Statistical comparisons were performed between the healthy 
elderly group and the AD group both before and after treat-
ment. These analyses were carried out to see whether any 
drug induced change resulted in restoration of age normal 
regional function. The direct comparison between the activa-
tion maps of the elderly group and those of the AD patients 
at baseline showed signiﬁ cant differences with lower levels 
of activation in the left precuneus in AD (Table 2b and Figure 
2b). The difference in activation in this region was no longer 
detectable when the AD patients’ post-treatment scans were 
used in the analysis.
Conversely, at baseline the AD group showed more 
activation than the elderly controls in the right middle frontal 
gyrus and the caudate bilaterally (corrected for multiple 
comparisons and when masking for deactivation in the elderly 
group) (Table 2b).
After treatment, signiﬁ cantly higher levels of activation 
in the AD group than the controls were found in the right 
inferior frontal gyrus and the left anterior cingulate (at the 
corrected level and when masking for deactivation in the 
elderly group) (Table 2b).
Working memory task – fMRI results
Elderly group
Signiﬁ cant activation was present in the right middle frontal 
gyrus, insula and precentral gyrus. No signiﬁ cant decreases in 
signal were found when correcting for multiple comparisons 
(Table 3a and Figure 3a).
AD group
No areas of signiﬁ cant activation were found in the baseline 
images of the AD patients at the chosen corrected threshold 
of signiﬁ cance. Signiﬁ cant decreases in signal were found in 
the right fusiform gyrus and the right parahippocampal gyrus 
(Table 3a and Figure 3b). After treatment, there were clusters 
of signiﬁ cant activation were larger, that survived correction for 
multiple comparisons and these included the right middle fron-
tal gyrus, the precentral gyrus, postcentral gyrus, and inferior 
parietal lobule. Decreases in signal were also more extensive 
Table 2 
b) (Continued)
Brain area Left/right Brodmann’s Talairach   Z value
   area coordinates  at local
    x y z maximum
Middle frontal gyrus R 47 28 36 −8 3.88
Superior frontal gyrus R 11 14 46 −10 2.94
Paracentral lobule R 31 4 −24 42 3.01
Parahippocampal gyrus R 36 18 −38 −22 3.10
Fusiform gyrus R 20 36 −36 −22 3.21
Elderly versus AD baseline       
Precuneus L 7 0 −54 47 3.35
Elderly versus AD after treatment      
No signifi cant differences.      
AD baseline versus elderly      
(masking for deactivation in elderly       
controls)      
Caudate nucleus (Body) L  −4 22 8 2.99
Middle frontal gyrus R 46 44 24 17 3.01
Caudate nucleus (Body) R  14 20 16 2.81
AD after treatment versus elderly      
(masking for deactivation in elderly       
controls)      
Anterior cingulate L 32 −16 39 13 3.67
Inferior frontal gyrus R 47 24 29 −10 3.94
Notes: *Z scores which correspond to p values corrected for multiple comparisons are highlighted in bold.
Neuropsychiatric Disease and Treatment 2008:4(2)472
McGeown et al
and included the left cingulate gyrus, middle temporal gyrus, 
superior temporal gyrus, precuneus, supramarginal gyrus, and 
the cerebellum bilaterally (Table 3a and Figure 3c).
Direct within subject comparisons of the image data from 
the AD patients at retest after treatment to those acquired at 
baseline showed signiﬁ cant differences in signal in the right 
inferior, middle, superior, and medial frontal gyri, in addi-
tion to the right precentral gyrus (Table 3b and Figure 4a). 
Conversely, the baseline versus retest comparison showed 
signiﬁ cant differences in left hemispheric areas, such as 
the precentral gyrus, middle frontal gyrus, insula, cingulate 
gyrus, and thalamus (when masking for deactivation in the 
AD group after treatment) (Table 3b).
Elderly/AD group comparisons
The comparison of the elderly controls to the patients at base-
line showed that the elderly activated the left precuneus and 
fusiform gyrus to signiﬁ cantly higher levels than the patients 
(Table 3b and Figure 4b). When the same comparison was 
carried out with the images of the AD patients acquired after 
treatment the elderly activated the left posterior cingulate and 
angular gyrus to a signiﬁ cantly higher level than the patients 
(Table 3b and Figure 4c).
When the baseline images of the AD patients were 
compared to those of the elderly control group signiﬁ cant 
differences were present and lower levels of activation were 
seen in the right cingulate gyrus, the left caudate and the 
left thalamus (when masking for deactivation in the elderly) 
(Table 3b). The AD patients after treatment activated the right 
middle frontal gyrus, postcentral gyrus, and supramarginal 
gyrus to higher levels than the elderly group (when masking 
for deactivation in the elderly) (Table 3b).
Discussion
Prolonged cholinesterase inhibitor treatment in patients 
with AD altered task related brain activity and the pattern 
of activity post-treatment appeared more like that of normal 
healthy elderly participants. At the behavioral level, the 
response was not uniform. There was a small non signiﬁ cant 
decrease in mean score and a lengthening of mean response 
time on the semantic task and a small, again non signiﬁ cant, 
increase in mean score and a shortening of mean response 
time on the working memory task. The range of behavioral 
response on the tasks probably reﬂ ected variation in drug 
efﬁ cacy across patients. Some people responded favorably 
to treatment, judging by their behavioral scores on the tasks 
and others did not. These variations in drug response probably 
weakened the collective detectable brain activation pattern 
of change in the group.
Semantic association task
Treatment increased levels of activation in areas involved 
with semantic processing. The significant cluster of 
activation in the left prefrontal cortex was larger after 
treatment, and the increase in activation in the left frontal 
cortex was conﬁ rmed in the direct before and after treatment 
within subject comparison. Increases in activation were 
detectable in the left inferior and middle frontal gyri, areas 
of the right prefrontal cortex, the left fusiform gyrus and 
the parahippocampal gyrus bilaterally. The activation of 
these areas has been reported in other neuroimaging studies 
in which the neural substrate of semantic processing has 
been studied in healthy people (Vandenberghe et al 1996; 
Price et al 1999; Ricci et al 1999; Sabsevitz et al 2005; 
Vandenbulcke et al 2007), which suggests that treatment was 
increasing activation in task relevant areas. The comparisons 
with the elderly showed that the AD patients after treatment 
had increased levels of activation in the left precuneus, to a 
level that the initial group difference in this area, present at 
baseline, was now no longer detectable. Treatment appeared, 
therefore, to have restored brain activity in this area to an age 
normal level. After treatment, the AD group also activated 
areas in the left hemisphere (in the temporal lobe) which 
Figure 1 Areas of signifi cant increases (red) and decreases (blue) in brain activa-
tion in the semantic association task detected in a) healthy elderly and in patients 
with AD b) before and c) after 20 weeks of treatment with rivastigmine.
Figure 2 Differences in activation between a) AD after treatment versus AD base-
line, and between b) healthy elderly versus AD patients at baseline in the semantic 
association task.
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Table 3 a) Areas of signifi cant differences in brain activation and deactivation in the elderly and in the AD patients (before and after 
20 weeks of treatment with rivastigmine) during the working memory task. b) Direct within and between group comparisons
a)
Brain area Left/right Brodmann’s Talairach   Z value
  area coordinates  at local
   x y z maximum*
Elderly – activations      
Middle frontal gyrus R 9, 46 36 11 25 3.64
Precentral gyrus R 6 48 1 28 4.34
Insula R 13 32 23 3 3.79
Elderly – deactivations      
No signifi cant deactivation at corrected       
level.      
AD (baseline) – activations      
No signifi cant activation      
AD (baseline) – deactivations      
Parahippocampal gyrus R 19, 37 30 −53 −7 3.99
Fusiform gyrus R 19 26 −63 −7 4.29
AD (after treatment) – activations      
Middle frontal gyrus R 8, 6 48 12 44 4.12
Precentral gyrus R 9 42 8 38 3.83
Postcentral gyrus R 40 40 −29 44 3.95
Inferior parietal lobule R 40 53 −46 45 4.14
AD (after treatment) – deactivations      
Middle temporal gyrus L 39 −46 −57 25 4.03
Superior temporal gyrus L 13 −36 −47 26 3.23
Supramarginal gyrus L 40 −57 −57 29 3.36
Precuneus L 7 −16 −54 40 3.16
Posterior cingulate L 30, 31 −6 −52 17 4.73
Cerebellum (Culmen) L  0 −53 −9 3.62
Cerebellum (Culmen) R  18 −55 −7 3.56
b)
Brain area – Brodmann area (BA) Left/right Brodmann’s Talairach   Z value
  area coordinates  at local
   x  y z maximum
AD baseline versus AD after treatment      
(masking for deactivation in AD after       
treatment)      
Middle frontal gyrus L 6 −32 2 39 2.68
Precentral gyrus L 4, 6 −61 −3 13 3.11
Cingulate gyrus L 31 −24 −27 40 2.61
Insula L 13 −42 −3 11 2.96
Thalamus L  −20 −21 16 2.75
AD after treatment versus AD baseline      
Inferior frontal gyrus R 9 46 5 27 2.59
Middle frontal gyrus R 9, 6 44 12 38 3.04
Superior frontal gyrus R 6 22 −8 65 2.60
Medial frontal gyrus R 6 6 −16 65 2.62
Precentral gyrus R 6 18 −18 65 2.68
(Continued)
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are normally associated with verbal semantic memory tasks 
(Davies et al 2004; Baldo et al 2006), to higher levels than 
the healthy elderly controls.
Although the AD patients showed increased activation 
in parts of the cortex thought to be involved in semantic 
processing, on average the behavioral scores decreased after 
treatment. Not all patients showed a decrement in behavioral 
scores following treatment, however. On the contrary, some 
showed remarkable improvements with treatment, while 
others did not. The range of change in behavioral scores 
on the semantic association task was large and might well 
have inﬂ uenced the overall pattern of brain activation seen 
at retest. The small sample size, however, does not provide 
enough statistical power to compute separate behavioral and 
imaging analyses for subgroups of patients responding and 
non responding to treatment.
Working memory task
The elderly participants activated the right prefrontal 
cortex, a brain region known to play a signiﬁ cant role in 
Table 3
b) (Continued)
Brain area – Brodmann area (BA) Left/right Brodmann’s Talairach   Z value
  area coordinates  at local
   x  y z maximum
Elderly versus AD baseline
Fusiform gyrus L 37 −46 −39 −8 3.52
Precuneus L 39, 19 −42 −68 35 3.81
Elderly versus AD after treatment      
Angular gyrus L 39 −40 −72 33 3.53
Posterior cingulate L 30, 31 −6 −52 17 5.06
AD baseline versus elderly      
(masking for deactivation in elderly       
controls)      
Thalamus L  −6 −7 21 3.03
Caudate nucleus (Body) L  0 12 16 2.61
Cingulate gyrus R 31 12 −22 34 2.80
AD after treatment versus elderly      
(masking for deactivation in elderly       
controls)      
Middle frontal gyrus R 6, 8, 9 34 1 53 3.34
Postcentral gyrus R 2, 40 55 −25 42 3.50
Supramarginal gyrus R 40 55 −41 35 4.09
Notes: *Z scores which correspond to p values corrected for multiple comparisons are highlighted in bold.
Figure 4 Differences in activation between a) AD after treatment versus AD baseline, 
and between healthy elderly versus AD patients at b) baseline and c) after treatment 
in the working memory task.
Figure 3 Areas of signifi cant increases (red) and decreases (blue) in brain activation 
in the working memory task detected in a) healthy elderly and in patients with 
AD b) before and c) after 20 weeks of treatment with rivastigmine.
Neuropsychiatric Disease and Treatment 2008:4(2) 475
Rivastigmine modulates brain activity in AD
attention and visual working memory (Posner and Raichle 
1997; Courtney et al 1998; Faw 2003). This aspect of right 
dorsolateral prefrontal cortex function would likely be a con-
tributor to successful completion of the working memory task 
as the letter stimulus became a target only when it matched the 
previous letter. When presented, each letter would have been 
held in visual working memory temporarily. This strategy 
might have been sufﬁ cient for the elderly controls to perform 
this task accurately, given that this condition had a very low 
working memory load in healthy individuals. N-back tasks 
with higher working memory loads, instead, appear to involve 
areas associated with phonological rehearsal and storage 
(Awh et al 1996; Braver et al 1997; Veltman et al 2003).
The patients with AD, after receiving treatment, activated 
the right middle frontal gyrus more extensively than at 
baseline. The right parietal cortex, which has a signiﬁ cant 
role in the orientation of attention (Corbetta et al 1995), was 
also activated after treatment. Direct comparison of the AD 
patients’ images after treatment with the pre-treatment images 
showed signiﬁ cant increased activation in the right prefrontal 
cortex. This increased activation following treatment with 
rivastigmine is task appropriate and overlaps with the area 
that was activated by healthy elderly. In terms of behavior, 
the increase in mean score after treatment was modest, and 
the difference between baseline and retest was not signiﬁ cant. 
In the same way, a previous fMRI study of mild cognitive 
impairment found increases in brain activation (after 5 days 
of treatment with galantamine), but no signiﬁ cant behavioral 
improvement on a face encoding task or when 0 and 1-back 
working memory task conditions were compared separately 
with baseline (Goekoop et al 2004). In the working memory 
task, as in the semantic task, the range of behavioral response 
was variable. Some people showed substantial increases and 
others decreases in performance after treatment. Variation in 
drug efﬁ cacy is an important confounding variable which 
should be taken into account when interpreting such data.
Conclusion
The evidence from this exploratory fMRI study of AD patients 
receiving rivastigmine treatment for a clinically relevant 
period supports the conclusions from a similar study using 
galantamine (Shanks et al 2007). Variable patient response 
to treatment and drug dynamic and kinetic factors in small 
groups of patients studied with fMRI will inevitably bias 
(either way) the effect size of any relevant drug related changes 
in BOLD signal. Clinical diagnosis is always provisional and 
diagnostic heterogeneity cannot be completely ruled out in 
clinical samples. At the same time, when a multifactorial 
approach to clinical diagnosis is used, diagnostic errors are 
minimized and in research samples diagnostic accuracy can 
equal or exceed that achieved post-mortem. Genetic factors, 
including APOE status and cholinesterase variants may 
also contribute to patterns of response, perhaps especially 
so with rivastigmine where there is an additional BuChE 
inhibitory action. In this AD group two patients were APOE 
ε4 allele homozygous and one had the BuChE K variant 
polymorphism, too few for any meaningful subgroup analyses 
of possible genetic inﬂ uences.
The detection of small modulatory changes in brain 
activation in task related areas, however, is encouraging, and 
may be a robust effect of ChEI therapy over longer periods in 
responding patients. It remains difﬁ cult to fully understand 
the clinical signiﬁ cance of published pharmacological fMRI 
studies of ChEI effects in AD, until clinical and behavioral 
responses can be adequately included as factors in the analy-
sis of imaging data. Response to treatment is already known 
to be an important modulator of changes in brain blood ﬂ ow 
and metabolism in a number of studies of ChEI effects in AD 
(Nobili et al 2002; Venneri et al 2002; Shimizu et al 2006). 
Routine clinical assessment of response to ChEIs, however, 
is based on simple screening tests and clinical impression, 
and often superﬁ cial stability is seen as a justiﬁ cation for con-
tinued therapy. An observer independent measure of beneﬁ t 
in terms of brain activation would better justify the costs of 
treatment for responders, and avoid prolonged unnecessary 
prescription with possible negative outcomes in those patients 
who are not responsive to treatment.
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